Skip to content

Released May 11, 2020, after the close

10-Q filed May 11, 2020, 41 days after period end · 0001564590-20-024213

Q1 2020 · 10-Q
Revenue$2.52M−4.4% vs Q1 2019−10.2% vs Q4 2019
Net Income-$33.52MN/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.44N/M vs Q1 2019N/M vs Q4 2019
Operating Income-$34,492,000N/M
Operating Cash Flow-$26,673,000N/M
Free Cash Flowderived-$27,743,000N/M
Margins · derived
Operating margin-1371.5%−594.6 pt vs Q1 2019
Net margin-1332.8%−582.0 pt vs Q1 2019

What the release said

The release

Same quarter

MetricQ1 2020Q1 2019Q1 2018Q1 2017
Revenue$2.52M$2.63M$1.03M$1.03M
Net Income-$33.52M-$19.76M-$14.14M-$10.13M
EPS Diluted-$0.44-$0.30-$0.27-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR